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Abstract: Enzyme therapies are attracting significant attention as thrombolytic drugs during the 
current scenario owing to their great affinity, specificity, catalytic activity, and stability. Among 
various sources, the application of microbial-derived thrombolytic and fibrinolytic enzymes to 
prevent and treat vascular occlusion is promising due to their advantageous cost–benefit ratio and 
large-scale production. Thrombotic complications such as stroke, myocardial infarction, pulmonary 
embolism, deep venous thrombosis, and peripheral occlusive diseases resulting from blood vessel 
blockage are the major cause of poor prognosis and mortality. Given the ability of microbial 
thrombolytic enzymes to dissolve blood clots and prevent any adverse effects, their use as a 
potential thrombolytic therapy has attracted great interest. A better understanding of the 
hemostasis and fibrinolytic system may aid in improving the efficacy and safety of this treatment 
approach over classical thrombolytic agents. Here, we concisely discuss the physiological 
mechanism of thrombus formation, thrombo-, and fibrinolysis, thrombolytic and fibrinolytic agents 
isolated from bacteria, fungi, and algae along with their mode of action and the potential application 
of microbial enzymes in thrombosis therapy. 
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1. Introduction 
Dysregulation of the intrinsic balance between the coagulation cascade 
and the fibrin- and thrombolytic pathways can lead to severe outcomes 
such as myocardial infarction, stroke, and massive pulmonary embolism 
caused by fibrin accumulation in the blood vessel walls, resulting in the 
formation of hemostatic plug or a clot [1]. Currently, the tissue 
plasminogen activator (tPA) or plasminogen activator (PA) is an 
indispensable clinical tool in thrombolytic therapy [2]. They are 
categorized into first, second, and third generation (Figure 1) [3]. PA are 
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serine proteases that form active plasmin from inactive plasminogen and 
mediate fibrin lysis through two modes of action: (i) direct—channels 
direct action on plasminogen to catalyze its activation; and (ii) indirect—
forms a 1:1 stoichiometric complex with plasminogen or plasmin followed 
by activation of the circulating plasminogen molecule. Despite their clinical 
effectiveness, however, these agents have several undesirable side effects, 
including immunogenicity, gastrointestinal bleeding, intracranial 
hemorrhage, and major systemic hemorrhage [4,5]. Consequently, there is 
an urgent need for approaches exploring new fibrinolytic agents with 
better specificity and efficacy. 
 
Figure 1. Generational classification and features of thrombolytic drugs. 
There are several known sources of fibrinolytic enzymes, including 
plants, animals, and microbes. Among them, microbial-derived fibrinolytic 
enzymes have gained particular interest because they possess the 
following advantages: (i) cost-effective production, (ii) fewer to no side 
effects [6], (iii) broad biochemical diversity, (iv) mass-culture feasibility, 
and (v) allow genetic manipulation. Hence, various microorganisms have 
been used for the isolation of fibrinolytic enzymes, including bacteria, 
fungi, and algae. 
The purpose of this review is to provide an overview of the microbial-
derived enzymes with thrombolytic and fibrinolytic potential and 
summarize the existing literature on the microbes proposed to produce 
enzymes with thrombolytic and fibrinolytic activities. 
1.1. Mechanism of Thrombus Formation 
Hemostasis is defined as the physiological process of cessation of blood 
loss by clot formation at the site of an injury. Fibrin is a major component 
of blood clots, and is formed from fibrinogen (large soluble plasma 
glycoprotein) via proteolysis by thrombin. The accumulation of fibrin clots 
results in thrombus formation. A thrombus is a blood clot formed within 
the blood vessel [7]. Under physiological conditions, a proteolytic 
enzyme—plasmin—hydrolyses the fibrin clot to prevent thrombosis in 
blood vessels. During vascular pathophysiology or damage to the vascular 
system, the process of clot hydrolysis is disrupted, which may result in 
thrombosis [8]. 
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Hemostasis and thrombosis are intricate, multifactorial processes. 
Platelets, in conjugation with endothelial cells and coagulation proteins, 
are the crucial mediator of vascular hemostasis and thrombosis. Disruption 
to any of these processes could result in atherosclerotic plaque formation 
[9–11] (Figure 2, leading to variety of thrombotic diseases including CVDs 
(cardiovascular diseases) [12,13], abdominal aortic aneurysms (AAAs) 
[14,15], pulmonary embolism (PE) [16], and stroke [17,18]. 
 
Figure 2. Innate immune cells in deep vein thrombosis (DVT). Adapted with permission from Mukhopadhyay et al., 
copyright © 2021 [11]. 
The process of hemostasis is divided into two stages: (1) primary 
(involves rapid platelet activation) and (2) secondary (requires additional 
coagulation pathways to form polymeric fibrin) processes (Table 1). 
Table 1. Overview of hemostasis [19–21]. 
Primary Hemostasis      
(Platelet Plug Formation) 
Secondary Hemostasis 
(Coagulation Cascade to Form Fibrin Network) 
● It is a response to endothelial disruption 
● It is the phase of strengthening and stabilization of the 
soft platelet plug formed at the site of injury. 
● Injured endothelium exposes the procoagulant 
subendothelial matrix and promptly initiates primary 
homeostasis, which comprises of following four 
sequential but overlapping phases: 
i. Vasoconstriction 
- Mediated by endothelin-1 
- Damaged endothelium exposes sub-endothelial 
collagen, von Willebrand factor (vWF), releases ATP, 
and inflammatory mediators 
● It initiates enzymatic activation of coagulation proteins 
to strengthen the soft platelet plug via stable fibrin clot 
formation, which involves several steps and can be 
divided into 3 pathways as follows: 
i. Extrinsic pathway 
- Initiates with binding of tissue factor (TF) and      factor 
VII (FVII), activating FVII to factor VIIa (FVIIa), 
forming a TF-FVIIa complex 
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ii. Platelet adhesion 
- Gp Ib-IX receptor on platelets binds to vWF 
iii. Platelet activation 
- Mediated via thrombin by 2 mechanisms: (1) 
Irreversible change in platelets shape from smooth discs 
to multi-pseudopodal plugs and (2) Secretion of 
cytoplasmic granules 
iv. Platelet aggregation 
- Gp IIb/IIIa receptors adhere to vWF and fibrinogen 
- TF-FVIIa complex activates factor X (FX) to get FXa, 
initiating common pathway described below—(iii) 
ii. Intrinsic pathway 
- Initiated with activation of FXIIa 
- FXIIa activates FXI to FXIa 
- FXIa activates FIX to FIXa 
- FIXa-factor VIII (FVIIIa) complex 
activates FX, initiating common pathway described 
below—(iii) 
iii. Common pathway 
- Factor Xa + Factor Va + calcium on phospholipid 
surfaces (prothrombinase complex) = activation of 
activating prothrombin (aka Factor II) to thrombin. 
- Thrombin activates FXIIIa 
- FXIIIa crosslinks with fibrin forming s     tabilized clot 
● Limits bleeding instantly ● Gradually      fibrinolysis will dissolve the stable plug 
1.2. Fibrinolysis and Thrombolysis 
Fibrinolysis is the breakdown of fibrin in the blood clot, and 
thrombolysis can be simply defined as the process of thrombus dissolution. 
Fibrin is a primary protein component of a blood clot that is formed 
from fibrinogen (340 kDa glycoprotein) by thrombin-mediated proteolysis 
and elimination of N-terminal fibrinopeptides from the Aα and Bβ chains. 
A serine protease, plasmin, is an activated form of inert plasma precursor, 
plasminogen (PLG). PLG is a 791-AA-long glycoprotein that circulates in 
blood plasma as an inactive zymogen. The plasmin is a crucial enzyme in 
the dissolution of fibrin clots. There exist two major glycoforms of human 
plasminogen, namely, type I (consists of two molecules of glycosylation) 
and type II (consists of one molecule of glycosylation) [8,22]. The binding 
of circulating PLG to the cell surface or blood clot acquires an open 
conformation, which aids in the formation of catalytically active plasmin 
by the Arg561-Val562 bond cleavage via a direct PLG activator [23]. Direct 
PA includes tissue plasminogen activator (tPA), streptokinase and 
urokinase or their variants [3,24]. Plasmin formation leads to fibrin lysis, 
giving soluble fibrin degradation products (FDPs) [22,25]. Therefore, the 
process of fibrinolysis involves two phases: (i) PLG activation on the 
surface of the fibrin clot to forms plasmin, which dissolves fibrin—i.e., a 
physiological process; and (ii) amplification of plasmin-induced clot 
breakdown by exposing the additional binding sites of degraded fibrin—
i.e., pharmacologically mediated processes such as fibrinolytic and 
thrombolytics. 
2. Microbes in Thrombolytic Therapy 
Many microbial-derived thrombolytic enzymes have been discovered 
and characterized. In general, the strains that produce thrombolytic 
enzymes are screened and isolated by using sterile skimmed milk agar 
with subsequent incubation of culture at 37 °C for 24 h; protease-positive 
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isolates form a hydrolytic zone, which is screened by fibrin plate assay [26–
29]. The fibrin plate assay is a precise and sensitive method to quantitate 
the extent of fibrin breakdown. Briefly, a fibrin clot covering the bottom of 
a petri dish is treated with the fibrinolytically active solutions, and then the 
relative amounts of fibrin (converted substrates) are measured by 
determining the areas of the lysed zones. These enzymes are produced via 
solid and liquid state fermentation in a medium enriched with carbon 
sources (such as cellulose, dextran, dextrose, fructose, starch, maltose, 
ribose, sucrose, galactose, and trehalose) and nitrogen sources (including 
organic-based (yeast extract, peptone, gelatin, urea, casein, tryptone, and 
soya meal) and inorganic salts (ammonium chloride, sodium dihydrogen 
phosphate, ammonium sulfate, ferrous sulfate, potassium nitrate, calcium 
chloride, ferrous sulfate, and disodium hydrogen phosphate)). Inhibitors 
such as ethylene glycol-bis(β-aminoethyl ether)-N,N,N′,N′-tetraacetic acid      
(EGTA), phenylmethylsulfonyl fluoride (PMSF), and 
ethylenediaminetetraacetic acid (EDTA); and metal ions (Cu2+, Co2+, Ca2+, 
Fe3+, Fe2+, K+, Mg2+, Mn2+, Na+, and Zn2+) are supplemented in the culture 
medium to further enhance the production process of thrombolytic 
enzymes [30,31]. One of the physiological advantages of microbial-derived 
thrombolytic enzymes is their stability at a wide range of pH values (5–11) 
and temperatures (30–70 °C). In addition, molecular cloning approaches 
abet the characterization of genes encoding target-specific modes of action 
with minimal side-effects, facilitating the potent application of 
thrombolytic enzymes in warfare for blood clotting disorders, discussed 
elsewhere in greater detail [32,33]. 
To overcome the associated drawbacks of currently available 
thrombolytic agents, various preliminary evaluation approaches are used 
to test the pharmacokinetics and dynamics of potential drug candidates of 
microbial origin with respect to their pharmacological cogency and clinical 
relevance. Briefly, in vitro and in vivo assays to assess the clot lysis 
properties of these agents are performed either by using fibrin as a direct 
substrate or by the production of a fibrin clot using thrombin. 
The in vitro assays include: (i) Antiaggregatory activity—measures 
reduction or inhibition of platelet aggregation [34]; (ii) Anticoagulant and 
thrombolytic activity—measures ability to prevent blood clot formation and 
dissolution of an existing blood clot [35,36]; (iii) Clot formation and lysis assay 
(CloFAL)—periodic quantitative measurement of clot lysis, aid in the 
clinical evaluation of net hemostatic balance, and bleeding and clotting 
disorders [37]; (iv) Euglobulin clot lysis assay—rapid and sensitive method 
of measuring fibrinolysis within the euglobulin fraction [38]; and (v) 
Thromboelastography (TEG)—the ability to measure the viscoelastic 
properties of the whole blood clot [39]. 
The in vivo assays include: (i) Carrageenan-induced thrombosis model—
helps assessment of clinically relevant anti-thrombus and thrombolytic 
agents by demonstrating disappearance of wine-colored thrombus [40]; (ii) 
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D—Dimer test—fibrin derivatives containing cross-linked D—dimer (XDP) 
domains help monitor fibrinolysis [41]; (iii) Ferric chloride-induced 
thrombosis model—aids in assessing anti-platelet and anticoagulant drugs 
[42]; and (iv) Rat groin flap model—an important tool in comparative 
analysis of various anticoagulants and vasomotor drugs [43]. In addition 
to promising a better understanding of the role of the drug candidate in 
alleviating disease pathophysiology and determining its therapeutic 
potential, the combination of in vitro and in vivo assays also provides 
propitious translational application of microbial-derived novel 
thrombolytic agents. 
2.1. Promising Microbial Producers of Thrombolytic Enzymes 
The past decade has witnessed a surge in the discovery of thrombolytic 
agents from numerous microbes, and this has kindled the development 
and characterization of microbial-derived agents with thrombolytic 
activity and minimal or no side effects. The known microbial producers of 
thrombolytic enzymes include bacteria, fungi, and algae. 
2.1.1 Bacteria 
Bacteria are the first-line sources because bacterial proteins are suitable 
for oral administration and facilitate large-scale production. (a) Bacillus sp. 
are among the most preferred sources; various strains have been reported 
to have fibrinolytic activity (Figure 3A). In addition, several other strains 
with fibrinolytic properties have been reported, although their mode of 
action is yet to be elucidated, such as Bacillus sp. DJ–2 [44], B. subtilis A26-
derived subtilisin BSF1 and BAF1 obtained from B. amyloliquefaciens An6 
[45,46], enzyme URAK produced by B. cereus NK1 [47], B. cereus GD 55-
derived protease [48], B. cereus IND1 [49] and B. halodurans IND18 [50] are 
the sources of       proteolytic enzymes that exhibit both thrombolytic 
activity and PLG activation properties, while a fibrinolytic protease with 
absolute clot dissolution ability in a short span of time (within 4 h) in in 
vitro conditions was obtained from Bacillus sp. IND12 [51], B. 
pseudomycoides strain MA02 [52], and B. cereus RSA1 [53]; (b) Streptomyces 
sp. are the largest fibrinolytic enzyme-producing genus. Figure 3B 
summarizes the fibrinolytic agents derived from different strains of 
Streptomyces sp.; (c) other bacterial sp. that have been reported to produce 
fibrinolytic enzymes are summarized in Figure 3C. Additionally, a 
proteolytic enzyme of ~50 kDa serrapeptase (SP) or serralysin derived from 
enterobacterium Serratia E–15 [54] was noted to have fibrinolytic potential 
[55] along with the ability to distinguish and dissolve only dead and 
damaged tissue without harming the living tissue [55], Treponema denticola 
was used to produce thrombolytic enzymes [56], proteases of 44 kDa and 
64 kDa obtained from Shewanella sp. IND20 and Psuedoalteromonas sp. 
IND11, respectively, showed direct clot lysis activity as well as PLG 
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activation ability [57,58], Paenibacillus sp. IND8 [59], and Stenotrophomonas 
maltophilia Gd2 were shown to possess robust fibrinolytic activity [30]. 
2.1.2 Fungi 
The enzymatic properties of fungal sp. are a novel and largely 
unexplored facet, and there exists exiguous literature on the fibrinolytic 
potential of these microorganisms. Fungi are considered a suitable source 
of thrombolytic enzymes because of their ability to grow on solid 
substrates like agro-industrial waste residues. Different fibrinolytic agents 
obtained from fungal species and their mechanism of action are outlined 
in Figure 4. Furthermore, Cochliobolus lunatus and Penicillium chrysogenum 
H9 were documented as fibrinolytic enzyme producers [60,61], 
metalloprotease with plasmin-like activity was produced by Fusarium 
pallidoroseum [62], purified Aspergillus ochraceus 513 was reported to 
possess both fibrinolytic and anticoagulant potential [63], Oidiodendron 
flavum is another fibrinolytic producer [64], serine protease isolated from 
Fusarium BLB were proposed to have fibrinolytic ability [65], 27.3 kDa 
fibrinolytic enzyme, CMase, is a metalloprotease produced from Cordyceps 
militaris [66,67], metalloprotease of 18.2 kDa obtained from a medicinal 
mushroom, Schizophyllum commune, was reported to have fibrin lysis 
activity [68], Aspergillus oryzae KSK-3-derived serine protease of 30 kDa 
exhibit thrombolytic potential [69], serine proteases from Bionectria sp. can 
be the potential treatment for thrombotic diseases [70], alkaline protease 
and metalloprotease obtained from Aspergillus strain KH 17 and Aspergillus 
brasiliensis AUMC 9735, respectively, were proposed to have robust 
fibrinolytic potential [71,72], and protease isolated from Mucor subtilissimus 
UCP 1262 via two different approaches—solid-state fermentation and 
aqueous two-phase system—were reported as a potential promising agent 
for the prevention and therapy against thrombosis [73]. 
2.1.3 Algae 
Algae are excellent sources of various biologically active agents with 
pleiotropic effects and are rich sources of food, feed, and energy. Few 
studies have evaluated the potential applications of algal-derived enzymes 
in fibrinolytic therapies (summarized in Figure 5), thus introducing a new 
era of bioprospecting of enzymes from algae for their role in thrombolytic 
activity.  









Figure 3. Bacterial-derived fibrinolytic enzymes and their mode of action. (A) Bacillus sp. [32,49,50,74–84]; (B) 
Streptomyces sp. [36,85–91]; (C) other bacterial species [92–100]. 




Figure 4. Fungal-derived enzymes with fibrinolytic potential and their mechanism of 
action.[5,31,66,101–115]. 




Figure 5. Fibrinolytic potential of algal-derived enzymes [113, 116–124]. 
3. Microbial-Derived Drugs in Thrombolytic Therapy 
3.1. Streptokinase 
Streptokinase (SK) is the most commonly used first-generation 
thrombolytic agent. It is a 47 kDa protein and comprises 414 amino acid 
(AA) residues and exhibits its maximum activity at pH ~7.5 [125]. SK is 
isolated and derived from several strains of β-hemolytic Streptococci of 
Lancefield group A, C, and G [126,127]. The Streptococcus equisimilis GCS 
strain H46A and group C have been chiefly used for SK production [128]. 
SK comprises three structural domains: α, β, and γ at the 1–146, 147–290, 
and 291–414 AA positions catenated by two flexible coil regions. SK has a 
half-life of ~30 min [129,130]. The thrombolytic potential of SK was first 
acknowledged by Johnson and Tillett in 1952, where they observed that 
artificially induced intravascular clots within the ear vein of rabbits via 
sodium morrhuate were successfully dissolved after intravenous infusion 
of SK [131]. 
Moreover, the large-scale purification of human plasminogen achieved 
by Kline [132] allowed the direct application of plasmin as a clot buster. 
However, the major solicitude associated with direct use of plasmin or SK-
mediated plasminogen activation may result in indiscriminate, systemic 
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plasmin generation and substantial diminution of circulating PLG and α-
2-antiplasmin [133,134], which can lead to a significant reduction in blood 
clotting ability, and consequently, a serious risk of hemorrhage. Hence, 
limiting the application of plasminogen activators as a therapeutic agent 
rather than circulating plasmin. Correspondingly, Tillette and Sherry 
reported accompanying adverse effects of SK, which causes pyogenic 
reactions with symptoms like arthralgia, occasionally nausea, and 
headache, etc., ergo, limiting the administration of multiple doses of SK 
[135]. Nevertheless, continued efforts have been made to achieve reduced 
pyrogenic reaction of SK by using various approaches such as structural 
and chemical modifications, liposomal entrapment or encapsulation, and 
domain fusion (Table 2); the recombinant SK (rSK) thus obtained possessed 
less antigenicity compared to wild-type SK [136,137]. Cloning the SK gene 
in non-pathogenic microbes permits the production of fortified rSK that 
eliminates the risk of infection by potentially pathogenic Streptococci [138]. 
3.1.1. Action Mechanism 
SK functions by hijacking the fibrinolysis cascade, where it 
stoichiometrically binds to plasminogen, inducing a conformational 
change in plasminogen to form an enzymatically active streptokinase–
plasminogen (SK-PLG) complex [139,140]. SK-PLG complex is a highly 
specific protease that further cleaves other circulating PLG molecules and 
is capable of converting them to active serine protease, plasmin, that can 
degrade the fibrin clot via its specific lysine binding site [141,142]. There 
are several functional regions across SK domains, including: (i) α domain—
the Asp41–His48 region between 1-59 AA residues regulates binding to 
PLG [140,143]. It additionally contains single residues (V19F, V35E, and 
S44K) for substitution that are crucial for SK-plasmin complex activation 
[142,144]; (ii) β domain—Lys 256, 257, and Val158–Arg219 region aid in 
PLG recognition, processing, and SK-plasmin complex formation [145]; 
and (iii) γ domain—a coiled region (Leu314-Ala342) that plays an essential 
role in stabilization of SK-micro plasmin complex for PLG activation. SK 
was the first Food and Drug Administration (FDA)-approved PLG 
activator for thrombosis therapy. 
3.1.2. A Potential Therapeutic Tool 
Several clinical trials have been designed to determine the therapeutic 
potential and safety of SK. These trials concluded the increased survival 
rate in patients receiving SK during the early onset of myocardial infarction 
(AMI) [146–148]. Ruegsegger and colleagues were the first to prove SK-
mediated intracoronary clot dissolution [149]. A subsequent study 
investigated the protective role of adjuvant intracoronary SK (ICSK) on 
late-phase infarct size and left ventricle volumes and functions in the 
setting of primary percutaneous coronary intervention (PCI). This study 
reported that immediate administration of a low dose of ICSK not only 
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limits the long-term infarct size but also preserves left ventricle volumes 
and functions [150]. SK is, therefore, the drug of choice in thrombolytic 
therapy, especially in developing countries due to its reduced cost. 
Table 2. Summary of strategies used for SK modifications. 










Lys59 and Lys386 
for glutamine 
















































3.2. Staphylokinase (SAK) 
SAK is a third-generation plasminogen activator obtained from 
Staphylococcus aureus GH38 which exerts its anti-thrombin activity by 
converting passive plasminogen to active plasmin. SAK is a 136 AA 
monomer of 15.5 kDa and comprises two equal-sized domains with flexible 
dumbbell shapes [95,158]. Structurally, it has been reported that AA at the 
26th position (methionine-26) is useful for PLG activation by SAK. 
Notably, the functional activity is lost if this AA is replaced with arginine 
or valine, whereas little or no effect on functional activity was observed by 
replacing it with leucine or cysteine [159]. SAK was precipitated: (i) initially 
from the supernatant fluid of cultures at pH around 3.3 with 10 mM HCL; 
and also (ii) at 75% saturation of (NH4)2SO4 (ammonium sulfate) [160,161]. 
The half-life of SAK is ~6 min [162]. Lewis and Sweet evaluated the in vitro 
fibrinolytic properties of SAK [163,164]. Correspondingly, Lewis and 
Kanae observed in vivo thrombolytic activity of SAK in dogs [165]. 
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3.2.1. Action Mechanism 
Fibrin degradation via SAK involves the following two steps: (i) 
formation of the SAK–PLG complex—this hydrolyzes a peptide bond 
between lysine 10 and 11 of SAK, which triggers peptide bond lysis 
between arginine 561 and valine 562 of PLG; (ii) resulting in the initial 
conversion of PLG to plasmin. SAK then binds to synthesized plasmin 
directly to catalyze the PLG conversion to plasmin [165]. α2-antiplasmin 
impedes the SAK-PLG or plasmin complex formation in the absence of 
fibrin [166,167]. However, the lysine binding domain of the complex is 
occupied in the presence of fibrin, preventing its inhibition by α2-
antiplasmin [158,168]. This suggests the fibrin-specific nature of SAK, and 
that it can therefore be a potentially potent thrombolytic therapy [158]. 
3.2.2. A Potential Therapeutic Tool 
THR-174 is the optimized form of the SAK sequence variant produced 
by ThromboGenics NV, Iselin, NJ, USA documented to have augmented 
efficacy and safety profiles in the pre-clinical trials (2012. Official Website. 
http://www.thrombogenics.com - Retrieved online on January 30th). 
Furthermore, the 3-D structure of the protein facilitated the design of 
PEG (polyethylene glycol) attachment sites, prolonging plasma half-life 
and reducing antigenicity [169–174]. A recent study reported that N-
terminal lipid modification of SAK fosters its activity, stability, and 
translocation across the blood–brain barrier (BBB), and therefore, holds 
great promise in treating diseases like stroke [175]. 
Studies have shown a key role of activated platelets in thrombosis, 
secondary clot formation, and blood vessel re-blocking. Following 
thrombolytic therapy, platelet aggregation promotes secondary clot 
formation. The coagulation cascade is activated by the ensuing clot lysis; 
in addition, a large amount of thrombin release elicits the platelets 
activation and aggregation. The activated platelets consequently inhibit 
fibrin lysis by tPA (tissue plasminogen activator) via the release of type I 
plasminogen activator inhibitor in the blood circulation, causing vessel re-
blockage [176]. Interestingly, RGD (arginine, lysine, and aspartic acid 
tripeptide)–SAK complex bind to GPIIb/IIIa (glycoprotein membrane 
receptor) at the platelet surface, which averts the binding of fibrinogen to 
this receptor, thereby precludes the activated platelets accumulation [168]. 
Moreover, several thrombin inhibitors combined with recombinant SAK 
(rSAK) are known to decrease secondary clot formation [177–182]. 
3.3. Nattokinase (NK) 
A serine protease derived from natto, a Japanese fermented food, was 
first extracted by Sumi and college [78] and was termed nattokinase. It is a 
275-AA-long single polypeptide chain of 27.7 kDa. Nattokinase possesses 
the inherent ability to boost the endogenous mechanisms to degrade the 
blood clots and is achieved via following different ways: (i) oral 
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administration—in vivo studies noted reduced euglobulin clot lysis time 
(ECLT), prolonged partial thromboplastin time (PATT), and averted 
platelet aggregation, therefore considered to be a direct-acting fibrinolytic 
enzyme [183,184]; (ii) intraduodenal administration—existing evidence 
support the transport of NK across the intestinal tract where it hydrolyzes 
the plasma fibrinogen [185]; (iii) efficacy—promotes fibrinolysis by 
degrading plasminogen activator inhibitor-1 (PAI-1) and aiding in plasmin 
formation by escalating the production of PLG activator [183,186]; and (iv) 
affinity—lower specificity and more affinity towards fibrinogen and cross-
linked fibrin, respectively [187]. In summary, use of NK has several 
advantages, including efficacy in clot lysis and restoration of arterial blood 
flow in contrast with plasmin and elastase [188]. 
Clinical Trials 
NK was shown to lower the plasma levels of fibrinogen FVII, and FVIII 
in two separate groups of patients undergoing dialysis and with 
cardiovascular risk factors without influencing blood lipids [189], 
enhanced fibrinolysis and anticoagulant activity [190], lower vWF levels 
[191], and is under Phase II trial to test its therapeutic ability against 
atherothrombosis [192]. 
3.4. Reteplase (Recombinant Plasminogen Activator, r-PA) 
Reteplase or r-PA (39 kDa) is produced in E. coli K12 as insoluble 
inclusion bodies and is an unglycosylated single-chain deletion variant of 
tPA. Comprised of 1–3 and 176–527 AA of tPA, it therefore only contains 
the catalytic protease domains and kringle 2, and is deficient in the finger, 
kringle 1, and epidermal growth factor of t-PA, as signified by the deletion 
of the Val4-Glu [193,194]. Since the kringle 1 domain of r-PA is crucial for 
its rapid renal clearance, loss of kringle 1 domain aids in extending the half-
life (~from 4 to 15 min) of r-PA [195,196]. Notably, the absence of the fibrin-
binding finger domain in r-PA decreases (~5-fold) its binding affinity 
towards fibrin [194,197]. Interestingly, patients with acute myocardial 
infarction (AMI) administered with a double bolus regimen (10 + 10 M after 
30 min) of r-PA showed robust thrombolysis activity [198,199]. 
Additionally, in The Global Use of Strategies to Open Occluded Coronary 
Arteries (GUSTO III) trial, hemorrhagic stroke frequency and mortality 
post-30 days were comparable in r-PA and alteplase [200]. r-PA is 
commercially available as Retavase® (Centocor, Inc., Malvern, PA, USA) 
and Rapilysin® (Roche) for AMI therapy. 
4. Use of Waste biomass/by-Products for Thrombolytic/Fibrinolytic 
Enzyme Production 
There is a constant search for novel and safer fibrinolytic enzymes all 
over the world owing to the short life cycle and allergic reactions caused 
by the tPA and certain fibrinolytic agents [201]. The microbial fibrinolytic 
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enzymes are quite economical, and have been studied in insects [202], 
marine organisms [203], and fermented foods [187,204]. Solid-state 
fermentation (SSF) is an efficient method for enzyme production and 
metabolite bioconversion. Agro-industrial waste, fishery waste, and 
wastewater can be used for the production of fibrinolytic enzymes. A wide 
variety of agro-wastes, such as groundnut husk [205], green gram husk 
[206], copra waste [207], deproteinized acid cheese whey and wheat bran 
[208], and cake of Jatropha curcas seed [201] have been effectively used for 
the production of enzymes. The solid substrate provides essential nutrients 
for both the growth of microbes and the production of enzymes. Various 
studies have shown that B. subtilis can produce a variety of fibrinolytic 
enzymes [209,210]. Vijayaraghavan and group [50] extracted fibrinolytic 
enzymes from Bacillus halodurans using agro-wastes. They observed wheat 
bran to be an efficient substrate for the production of fibrinolytic enzymes 
which could degrade fibrin clot thus behaving as an effective thrombolytic 
agent. Wu et al. [211] developed a cost-effective method to optimize the 
parameters of fermentation for the production of fibrinolytic enzymes by 
Bacillus subtilis WR350. Their results revealed that sucrose can be used as a 
low-cost substrate for the production of the fibrinolytic enzyme in a 100-L 
fermenter by B. subtilis WR350. Fish wastes also act as good substrates for 
the production of fibrinolytic enzymes due to their high nutrient content 
[212]. Biji et al. [201] produced fibrinolytic enzymes by Bacillus cereus IND5 
using cow dung and cuttlefish waste in SSF. The purified enzyme obtained 
had a specific activity of 364.5 U/g proteins, the molecular weight of 47 
kDa, stability at pH 8.0, high activity at 50 °C and was shown to possess 
fibrinolytic properties. Thus, the mixture of cuttlefish waste and cow dung 
had great applications as solid substrates for the production of fibrinolytic 
enzymes. Hence, use of waste biomass not only yields cost-effective and 
efficient fibrinolytic enzymes, but also reduces the chances of 
environmental pollution. 
5. Conclusions and Future Perspectives  
Vascular occlusion remains a major cause of morbidity and mortality 
worldwide. Although numerous thrombolytic agents have been identified 
and characterized from diverse sources, promising scientific data available 
from in vitro and in vivo studies have failed to translate into clinical trials 
successfully. Therefore, continuous efforts are needed in the search for 
more efficacious, safer, and cost-effective thrombolytic drugs. Microbial-
derived thrombolytic agents represent a step towards a potent approach in 
the prevention and treatment of vascular diseases such as CVDs, stroke, 
transient ischemic attack (TIA), PE, AAAs, venous thromboembolism 
(VTE), etc. Several thrombolytic enzymes have been reported to be isolated 
from microbial sources with therapeutic application in vascular diseases 
and have been shown to possess the following advantages over currently 
available treatment strategies: (i) extended plasma half-life, (ii) increased 
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fibrin specificity, (iii) high therapeutic index, (iv) lower allergic response, 
and (v) reduced risk of bleeding complications. Therefore, they promise 
efficacious translational potential. Both PLG activators and plasmin-like 
enzymes have been reported to exhibit these advantages. Thus, 
thrombolytic and fibrinolytic enzymes isolated from microbial sources 
would spur novel therapeutic strategies for advancing the prospects of 
these microbial-derived enzyme complexes in the therapeutic 
armamentarium of drugs. 
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